Wednesday, July 8, 2026
🇺🇸 FDA

biotech · Hypoglycemia · Diabetes Mellitus, Type 1 · XERS

Xeris Biopharma Holdings

Xeris Biopharma Holdings clinical programs — 16 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Chicago, USA HQ
2005 Founded
496 Employees
Public company Type
XERS · NYSE Ticker
Company details
Status
Public
HQ
Chicago, USA
Founded
2005
Employees
496
Programs
16
Drugs
12
Patents
24
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

Xeris Biopharma Holdings projects

16 ClinicalTrials.gov programs sponsored by Xeris Biopharma Holdings.

Xeris Biopharma Holdings has 16 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

16 programs

Clinical programs

  1. G-Pen

    Xeris Biopharma Holdings

    Insulin Hypoglycemia

    phase 3 small molecule completed

    1 trial

  2. G-Pen (glucagon injection)

    Xeris Biopharma Holdings

    Hypoglycemia

    phase 3 small molecule completed

    1 trial

  3. Glucagon

    Xeris Biopharma Holdings

    Diabetes Mellitus, Type 1

    phase 3 small molecule completed

    1 trial

  4. G-Pen Mini™ (glucagon injection)

    Xeris Biopharma Holdings

    Hypoglycemia

    phase 2 small molecule completed

    1 trial

  5. G-Pen Mini™ (glucagon injection)

    Xeris Biopharma Holdings

    Diabetes Mellitus, Type 1

    phase 2 small molecule completed

    2 trials

  6. G-Pen(TM) 1 mg

    Xeris Biopharma Holdings

    Hypoglycemia

    phase 2 small molecule completed

    1 trial

  7. G-Pump™ (glucagon infusion)

    Xeris Biopharma Holdings

    Hypoglycemia

    phase 2 small molecule completed

    1 trial

  8. Glucagon

    Xeris Biopharma Holdings

    Hypoglycemia

    phase 2 small molecule completed

    1 trial

  9. Glucagon

    Xeris Biopharma Holdings

    Congenital Hyperinsulinism

    phase 2 small molecule completed

    1 trial

  10. Glucagon RTU

    Xeris Biopharma Holdings

    Hyperinsulinemic Hypoglycemia

    phase 2 small molecule completed

    1 trial

  11. Glucagon RTU Injection With Insulin Pump Reduction

    Xeris Biopharma Holdings

    Hypoglycemia

    phase 2 small molecule completed

    1 trial

  12. Novo Nordisk GlucaGen®

    Xeris Biopharma Holdings

    Hypoglycemia

    phase 2 small molecule completed

    1 trial

  13. PRAM9

    Xeris Biopharma Holdings

    Diabetes Mellitus, Type 1

    phase 2 small molecule completed

    1 trial

  14. glucagon

    Xeris Biopharma Holdings

    Post-bariatric Hypoglycemia

    phase 2 small molecule completed

    1 trial

  15. levothyroxine sodium

    Xeris Biopharma Holdings

    Hypothyroidism

    phase 2 small molecule completed

    1 trial

  16. XeriSol glucagon

    Xeris Biopharma Holdings

    Type1diabetes

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Xeris Biopharma Holdings have?

16 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.